Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review

      Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review

      Medical Dialogues Bureau13 Feb 2020 9:45 AM IST
      Capmatinib (INC280) is an investigational, oral, potent and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the...
      Wockhardt sells Baddi plant, 62 drug brands to Dr Reddys for Rs 1850 crore

      Wockhardt sells Baddi plant, 62 drug brands to Dr Reddys for Rs 1850 crore

      Medical Dialogues Bureau12 Feb 2020 5:23 PM IST
      Commenting on the acquisition, Dr Reddy's Co-Chairman and Managing Director G V Prasad said," the acquired portfolio shall enhance Dr Reddy''s...
      Granules India gets tentative USFDA nod for generic Colchicine capsules

      Granules India gets tentative USFDA nod for generic Colchicine capsules

      Medical Dialogues Bureau12 Feb 2020 2:34 PM IST
      New Delhi: Drug firm Granules India on Tuesday said it has received tentative approval from the US health regulator for its generic Colchicine...
      Sun Pharma arm- SPARC application for cancer drug Taclantis rejected by USFDA

      Sun Pharma arm- SPARC application for cancer drug Taclantis rejected by USFDA

      Medical Dialogues Bureau12 Feb 2020 1:10 PM IST
      "The company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application...
      J B Chemicals Gujarat unit gets EIR from USFDA

      J B Chemicals Gujarat unit gets EIR from USFDA

      Medical Dialogues Bureau12 Feb 2020 1:03 PM IST
      The company has received EIR from the United States Food and Drug Administration (USFDA) for its newly set up and commissioned solid oral dosage forms...
      Zydus Cadila gets USFDA nod for Fluocinonide cream to treat skin conditions

      Zydus Cadila gets USFDA nod for Fluocinonide cream to treat skin conditions

      Medical Dialogues Bureau12 Feb 2020 12:51 PM IST
      Fluocinonide cream USP, 0.1 per cent, approved by USFDA is indicated to treat a variety of skin conditions such as psoriasis, eczema, dermatitis,...
      Sanofi asks US court to halt diabetes drug patent fight with Mylan

      Sanofi asks US court to halt diabetes drug patent fight with Mylan

      Medical Dialogues Bureau12 Feb 2020 10:30 AM IST
      In a stay application filed on Friday, Sanofi said a recent U.S. Court of Appeals for the Federal Circuit decision upholding the invalidation of two...
      Cadila Healthcare Ahmedabad facility gets EIR from USFDA

      Cadila Healthcare Ahmedabad facility gets EIR from USFDA

      Medical Dialogues Bureau11 Feb 2020 12:09 PM IST
      The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying...
      Zealand Pharma to acquire insulin pump maker Valeritas for USD 23 million

      Zealand Pharma to acquire insulin pump maker Valeritas for USD 23 million

      Medical Dialogues Bureau11 Feb 2020 11:30 AM IST
      The agreement with Zealand Pharma, which was reached following a robust and extensive marketing process, provides total cash consideration of $23...
      Roche Alzheimers disease drug fails to meet primary goal

      Roche Alzheimers disease drug fails to meet primary goal

      Medical Dialogues Bureau11 Feb 2020 11:30 AM IST
      Basel: Roche, recently announced that the gantenerumab arm of Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an...
      Nestle invests $200 million more in Aimmune after peanut allergy drug approval

      Nestle invests $200 million more in Aimmune after peanut allergy drug approval

      Medical Dialogues Bureau10 Feb 2020 8:05 PM IST
      (Reuters) - Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the...
      JB Chemicals Gujarat unit passes USFDA inspection with one observation

      JB Chemicals Gujarat unit passes USFDA inspection with one observation

      Medical Dialogues Bureau10 Feb 2020 8:04 PM IST
      NEW DELHI: JB Chemicals and Pharmaceuticals on Monday said its Gujarat unit has passed the US health regulator's periodical inspection with one minor...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok